Bosh sahifaBHM0 • FRA
add
BACHEM HOLDING AG
Yopilish kursi
78,35 €
Kunlik diapazon
74,55 € - 74,55 €
Yillik diapazon
51,25 € - 81,50 €
Bozor kapitalizatsiyasi
5,26 mlrd CHF
Oʻrtacha hajm
28,00
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
SWX
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (CHF) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 191,04 mln | 4,70% |
Joriy xarajat | 4,65 mln | -61,22% |
Sof foyda | 49,35 mln | 17,36% |
Sof foyda marjasi | 25,83 | 12,11% |
Har bir ulushga tushum | — | — |
EBITDA | 63,83 mln | 9,45% |
Amaldagi soliq stavkasi | 1,53% | — |
Balans
Jami aktivlari
Jami passivlari
| (CHF) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 30,99 mln | -67,45% |
Jami aktivlari | 2,11 mlrd | 9,66% |
Jami passivlari | 650,41 mln | 22,28% |
Umumiy kapital | 1,46 mlrd | — |
Tarqatilgan aksiyalar | 74,94 mln | — |
Narxi/balansdagi bahosi | 4,03 | — |
Aktivlardan daromad | 5,95% | — |
Kapitaldan daromad | 8,26% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (CHF) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 49,35 mln | 17,36% |
Operatsiyalardan naqd pul | 92,80 mln | 220,31% |
Sarmoyadan naqd pul | -89,05 mln | -624,68% |
Moliyadan naqd pul | -2,81 mln | -391,01% |
Naqd pulning sof oʻzgarishi | 923,00 ming | -94,31% |
Boʻsh pul | -43,10 mln | -92,30% |
Haqida
Bachem Holding AG is a Swiss biotechnology company specializing in the development and manufacture of peptides and complex organic molecules for use as active pharmaceutical ingredients. The company focuses on peptide-based therapeutics, including large-scale commercial production and process development for pharmaceutical applications. It was founded in 1971 and is a subsidiary of Ingro Finanz AG.
The head office is in Bubendorf in the canton of Basel-Landschaft. Bachem operates production facilities in Vionnaz, Vista and Torrance, and St Helens, as well as a sales and distribution site in Tokyo.
Bachem is one of the largest manufacturers of peptide-based APIs globally, supplying pharmaceutical and biotechnology companies with products used in both clinical development and commercial therapies.
In recent years, the company has expanded its manufacturing capacity, including new large-scale production facilities in Switzerland and the United States.
At the end of 2025, the company employed 2,511 people, reported revenue of CHF 695.1 million, and net income of CHF 148.8 million. Wikipedia
CEO
Tashkil etilgan
1971
Sayt
Xodimlar soni
2 363